Sodium‐glucose co‐transporter‐2 inhibitor use and dietary carbohydrate intake in Japanese individuals with type 2 diabetes: Arandomized, open‐label, 3‐arm parallel comparative, exploratory study
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
This study investigated the safety and efficacy of the sodium‐glucose co‐transporter‐2 ( SGLT2 ) inhibitor luseogliflozin with differing carbohydrate intakes in J apanese individuals with type 2 diabetes ( T2D ). Participants were randomly assigned to 3 carbohydrate‐adjusted meals for 14 days (days 1‐14; a high carbohydrate [ HC ; 55% total energy carbohydrate] and high glycaemic index [ HGI ] meal; an HC [55% total energy carbohydrate] and low glycaemic index [ LGI ] meal; or a low carbohydrate [ LC ; 40% total energy carbohydrate] and HGI meal). All participants received luseogliflozin for the last 7 days (days 8‐14), continuous glucose monitoring ( CGM ) before and after luseogliflozin treatment (days 5‐8 and days 12‐15) and blood tests on days 1, 8 and 15. Luseogliflozin significantly decreased the area under the curve and mean of CGM values in all 3 groups similarly. Fasting plasma glucose, insulin and glucagon were similar at all time points. Ketone bodies on day 15 were significantly higher in the LC‐HGI group compared with the HC‐HGI and HC‐LGI groups. In conclusion, luseogliflozin has similar efficacy and safety in J apanese people with T2D when meals contain 40% to 55% total energy carbohydrate, but a strict LC diet on this class of drug should be avoided to prevent SGLT2 inhibitor‐associated diabetic ketoacidosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients
Ferrannini, E., Muscelli, E., Frascerra, S., Baldi, S., Mari, A., Heise, T., Broedl, U. C., & Woerle, H.-J. (2014) · Journal of Clinical Investigation · doi:10.1172/jci72227 · Cited by 1,134
Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production
Merovci, A., Solis-Herrera, C., Daniele, G., Eldor, R., Fiorentino, T. V., Tripathy, D., Xiong, J., Perez, Z., Norton, L., Abdul-Ghani, M. A., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci70704 · Cited by 795
Rosenstock, J., & Ferrannini, E. (2015) · Diabetes Care · doi:10.2337/dc15-1380 · Cited by 664
Ogawa, W., & Sakaguchi, K. (2016) · Journal of Diabetes Investigation · doi:10.1111/jdi.12401 · Cited by 307 · cited 2×
“While the euglycaemic DKA cases reported in the USA were mostly in insulindependent T1D,(4,5) a number of euglycaemic DKA cases have been reported in Japanese people with T2D receiving SGLT2 inhibitors.(6) This difference might be attributable to the fact that T2D in EastAsian populations, including Japanese populatio…”
BackgroundResultDeFronzo, R. A., Hompesch, M., Kasichayanula, S., Liu, X., Hong, Y., Pfister, M., Morrow, L. A., Leslie, B. R., Boulton, D. W., Ching, A., et al. (2013) · Diabetes Care · doi:10.2337/dc13-0387 · Cited by 293 · cited 1×
“UGE occurs when plasma glucose levels are higher than the renal threshold and SGLT2 inhibitor treatment lowers the threshold.(15) Because glucose profiles of the HC-LGI and LC-HGI groups were similar and lower than in the HC-HGI group before and after luseogliflozin treatment in the present study (Figure S3 and Table…”
ResultEvidence-based practice guideline for the treatment for diabetes in Japan 2013
Tajima, N., Noda, M., Origasa, H., Noto, H., Yabe, D., Fujita, Y., Goto, A., Fujimoto, K., Sakamoto, M., & Haneda, M. (2015) · Diabetology International · doi:10.1007/s13340-015-0206-2 · Cited by 154
Self-citationHayami, T., Kato, Y., Kamiya, H., Kondo, M., Naito, E., Sugiura, Y., Kojima, C., Sato, S., Yamada, Y., Kasagi, R., et al. (2015) · Journal of Diabetes Investigation · doi:10.1111/jdi.12330 · Cited by 115
Pearce, K. L., Noakes, M., Keogh, J., & Clifton, P. M. (2008) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/87.3.638 · Cited by 80
Cited by
Sodium-Glucose Co-transporters and Their Inhibition: Clinical Physiology
Ferrannini, E. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.04.011 · Cited by 340
Sainsbury, E., Kizirian, N. V., Partridge, S. R., Gill, T., Colagiuri, S., & Gibson, A. A. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.02.026 · Cited by 268
Ketoacidosis associated with SGLT2 inhibitor treatment: analysis of FAERS data
Blau, J. E., Tella, S. H., Taylor, S. I., & Rother, K. I. (2017) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2924 · Cited by 271
Tamura, Y., Omura, T., Toyoshima, K., & Araki, A. (2020) · Nutrients · doi:10.3390/nu12113367 · Cited by 224
Sievenpiper, J. L., Chan, C. B., Dworatzek, P. D., Freeze, C., & Williams, S. L. (2018) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.10.009 · Cited by 200
Metadata
- Authors
- Yabe, D., Iwasaki, M., Kuwata, H., Haraguchi, T., Hamamoto, Y., Kurose, T., Sumita, K., Yamazato, H., Kanada, S., & Seino, Y.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2017-02-21
- Volume
- 19
- Issue
- 5
- Pages
- 739-743
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2593546451
- Cited by
- 67
- References
- 8
- FWCI
- 9.53
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Sodium‐glucose co‐transporter‐2 inhibitor use and dietary carbohydrate intake in Japanese individuals with type 2 diabetes: Arandomized, open‐label, 3‐arm parallel comparative, exploratory study. https://app.cochat.ai/papers/10.1111/dom.12848
- The paper
- Yabe, D., Iwasaki, M., Kuwata, H., Haraguchi, T., Hamamoto, Y., Kurose, T., Sumita, K., Yamazato, H., Kanada, S., & Seino, Y. (2017). Sodium‐glucose co‐transporter‐2 inhibitor use and dietary carbohydrate intake in Japanese individuals with type 2 diabetes: Arandomized, open‐label, 3‐arm parallel comparative, exploratory study. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.12848
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.